We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Niox Group Plc | LSE:NIOX | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.40 | 0.60% | 67.60 | 105,800 | 16:35:14 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 67.20 | 67.60 | 67.60 | 67.20 | 67.60 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 33.3M | 16.1M | 0.0383 | 17.55 | 282.54M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:47:01 | O | 103 | 67.595 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 22/4/2024 | 16:37 | UK RNS | Niox Group PLC Notice of 2024 Annual General Meeting |
| 05/4/2024 | 15:10 | UK RNS | Niox Group PLC Director/PDMR Shareholding |
| 04/4/2024 | 14:10 | UK RNS | Niox Group PLC Dividend Timetable |
| 03/4/2024 | 13:00 | UK RNS | Niox Group PLC Director/PDMR Shareholding |
| 03/4/2024 | 09:00 | UK RNS | Niox Group PLC Replacement: Block listing Interim Review |
| 02/4/2024 | 17:50 | UK RNS | Niox Group PLC Block listing Interim Review |
| 02/4/2024 | 13:45 | UK RNS | Niox Group PLC Replacement: Director/PDMR Shareholding |
| 28/3/2024 | 16:45 | UK RNS | Niox Group PLC Director/PDMR Shareholding |
| 28/3/2024 | 15:00 | UK RNS | Niox Group PLC Grant of options |
| 27/3/2024 | 14:00 | UK RNS | Niox Group PLC Exercise of SAYE Options |
Niox (NIOX) Share Charts1 Year Niox Chart |
|
1 Month Niox Chart |
Intraday Niox Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/4/2024 | 12:10 | NIOX GROUP - expertise in asthma diagnosis and management | 158 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:47:02 | 67.60 | 103 | 69.62 | O |
| 15:47:02 | 67.60 | 103 | 69.62 | O |
| 15:38:39 | 67.60 | 13,854 | 9,365.30 | AT |
| 15:35:26 | 67.60 | 722 | 488.07 | AT |
| 15:35:14 | 67.60 | 3,223 | 2,178.75 | UT |
| Top Posts |
|---|
Posted at 25/4/2024 09:20 by Niox Daily Update Niox Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NIOX. The last closing price for Niox was 67.20p.Niox currently has 420,442,112 shares in issue. The market capitalisation of Niox is £282,537,099. Niox has a price to earnings ratio (PE ratio) of 17.55. This morning NIOX shares opened at 67.60p |
Posted at 23/2/2024 18:18 by earwacks I think it’s held up well considering The uk is the worst performing market in the world and many British companies make most of their money in global business.This is a recent high for NIOX. It is similar to share price movement last year between update and actual results. News on dividend and cash position should help re establish the share price Then of course there is the expectant takeover by AZN Why else would they hold 16 percent of the. Company? Gl all |
Posted at 10/1/2024 07:51 by earwacks Niox would be the perfect complement in diagnosing severe asthma and managing the right level of treatment surely. FeNo being the gold standard in accurately measuring the exact inflammation of the airways |
Posted at 09/1/2024 22:45 by p1nkfish Noted the GSK addition to their asthma portfolio today.I no longer hold NIOX but wish you all well. |
Posted at 19/12/2023 06:03 by earwacks Paul Hill catches up with GuyHarwood on his various funds. Brief mention of Niox and the home kit. Suggests they would need a partner to get this to retail. Well we know for a fact they have set aside money ( 2 million) for the home kit, and aside from that it sounds like the accelerating cash generation is set to continue with solid dividend cover. I listen with great interest to his other life science projects which all seem to need funding in some way at a very difficult time.They have no tax to pay for yonks due to the unbelievable tax loss carry over of 600 million! So what are they going to do with the ever expanding cash pile? Richard Griffiths still reducing gradually and still the largest holder. Clearly someone is happy to take them off his hands but maybe what has halted the rise of the share price for now. With the share price seemingly consolidating around this level looks a good opportunity to add. As keen as I am to diversify, I just can’t see a better case for investing than here. I particularly like that they don’t really push this stock. They don’t need to, the numbers do the talking! Still up for a buy out but the sales will quickly catch up the premium rating PE of 22, not actually that expensive for a company with high teens revenue growth and great margins with recurring refill product. Gl |
Posted at 26/9/2023 10:38 by earwacks Yes Mufster they seem to have left off 2 top holders griffiths 27 percent and perhaps more interestingly Astra Zenica T 17 percent. No accounting for market madness right now. Even though this list is from last year Griffiths has been in it for sometime , maybe increasing his holding along the way but has always had a pretty big holding. Not sure when Astra got on board but obviously most think they will buy Niox at some stage. How much more do they want to pay? Seems bonkers |
Posted at 25/8/2023 10:09 by joseph moran DividendNIOX Niox Group AIM 2.5p 07-Jun-23NIOX 07-Jun-23 Dividend Announcement Ex-Dividend Date 17-Aug-23 Payment Date 15-Sep-23 |
Posted at 18/7/2023 08:09 by edwardt Boom! Seems like we are breathing life into share price as well as folks lungs |
Posted at 18/5/2023 07:08 by bc4 NIOX GROUP PLCAGM Statement Oxford, UK - 18 May 2023: NIOX Group plc (AIM: NIOX), a medical device company focused on point of care asthma diagnosis and management, is holding its Annual General Meeting today at the Hayakawa Building, Edmund Halley Road, Oxford Science Park. Oxford OX4 4GB. Trading Update We are pleased to report that our business has continued to perform well, with total revenues in the first 4 months of the year up 21% compared with the same period in 2022. Our core Clinical business grew strongly with revenues up 28% compared with the same period in 2022. EMEA has continued to experience strong growth, and our Asia markets have also improved significantly. In the USA, our relatively new distributor partners are starting to make an increasing contribution to revenues in the region, which were up 16% year to date compared with 2022.Ian Johnson, NIOX's Executive Chairman, said: "I am pleased to report a continuing strong trading performance in the year to date, reflecting the successful execution of our strategy. The effect of the growth in revenues, robust margins and the lower level of overheads means that adjusted EBITDA for the full year is now likely to be significantly higher than management expectations at the start of the year. The Board believes that the cash generation and resources of the Group are now at a level where it is appropriate to commence the payment of a dividend. Further details of the timing and quantum of an initial dividend payment will be announced in due course. It does not get any better than that great update |
Posted at 16/5/2023 15:07 by bc4 Taken from NIOX websiteFeNO by NIOX® Introducing a simple and easy way to transform your asthma care.By accurately assessing airway inflammation, FeNO testing can help improve asthma patient outcomes in one simple test, right at the point-of-care. Trusted around the world With over 45 million FeNO tests completed worldwide, NIOX® is trusted by thousands of healthcare professionals every day. Find out how FeNO by NIOX® can help make your asthma care easier. |
Posted at 08/3/2023 10:34 by earwacks Hold? Yesterday over 7.6 million sold and share price goes up. Today a 100 bot trade takes the share price down to 48p! Crazy. Trend is undeniable though:) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
